Atypical neuroleptics in the treatment of refractory obsessive-compulsive disorder;Atypická neuroleptika v léčbě rezistentní obsedantně-kompulzivní poruchy

Psychiatrie

Volumn 6, Issue 4, 2002, Pages 222-229

  Bareš, Martin ^a,b   Záleský, Richard ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Clozapine; Obsessive compulsive disorder; Olanzapine; Quetiapine; Risperidone; Serotonin reuptake inhibitors; Treatment resistance

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOZAPINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PINDOLOL; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; OBSESSIVE COMPULSIVE DISORDER; REVIEW; SIDE EFFECT;

EID: 0036457960     PISSN: 12117579     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Alonso P, Pujol J, Cardoner N, Beniloch L, Deus J, Menchon JM, Capdevila A, Valejjo J. Right prefrontal transcranial magnetic stimulation in obsessive-compulsive disorder. Am J Psychiatry 2001;158:1143-1145.
2. Andrade C. Risperidone may worsen fluoxetine-treated OCD. J Clin Psychiatry 1998;59:255-256.
3. Armaca M, Kuloglu M, Gecici O. Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: A single blind, placebo-controlled study. Int Clin Psychopharmacol 2002;17:115-119.
4. th Annual Meeting of the American Psychiatric Association 2001; New Orleans, Abstract Nr. 636.
5. Bogetto F, Bellino S, Vachetto P, Ziero S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder/OCD/: A 12-week open trial. Psychiatry Research 2000;96:91-98.
6. Callaghan JT, Berstrom JT, Ptak RF, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999;37:177-193.
7. Crewe HK, Lennard MS, Rocker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6/CYP2D6/activity in human liver microsomes. Br J Pharmacol 1992;34:262-265.
8. Dannon PN, Samson Y, Hirschmann S, Iancu I, Grunhaus LJ, Zohar J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: A double-blind placebo controlled trial. European Neuro-psychopharmacology 2000;10:165-169.
9. De Haan L, Beuk N, Hoogenborn B, Dingemans P, Linszen D. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone. A prospective study of 113 patients with recent-onset schizophrenia or related disorders. J Clin Psychiatry 2002;63:104-107.
10. Dennys D, Van Megen H, Westenberg H. Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: An open-label study. J Clin Psychiatry 2002;63:700-703.
11. Fineberg N. Refining treatment approaches in obsessive-compulsive disorder. International Clinical Psychopharmacology 1996;11(Suppl. 5):13-22.
12. Francobandiera G. Olanzapine augmentation of serotonin uptake inhibitors in obsessive-compulsive disorder: An open study. Can J Psychiatry 2001;46:356-358.
13. Ghaemi SN, Zarate CA, Popli AP, Piplat SS, Cole JO. Is there a relationship between clozapine and obsessive-compulsive disorder?: A retrospective chart review. Comprehensive Psychiatry 1995;36:267-270.
14. Goodman WK, McDougle CJ, Price LH, Barr LC, Hilus OF, Caplik JF, Charney DS, Henninger GR. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: Absence of symptom exacerbation. Biol Psychiatry 1995;38:138-149.
15. Goodman WK, Price LH, Passmussen SA et al. The Yale-Brown Obsessive Compulsive Scale /Y-BOCS/, I: Development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
16. Goodman WK, Price LH, Rassmussen SA et al. The Yale-Brown Obsessive Compulsive Scale /Y-BOCS/, II: Development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011.
17. Goodman WK, Price LH, Rassmussen SA et al. The Yale-Brown Obsessive Compulsive Scale/Y-BOCS/, II: Validity. Arch Gen Psychiatry 1989; 46:1012-1016.
18. Goodman WK. Obsessive-compulsive disorder: Diagnosis and treatment. J Clin Psychiatry 1999;60(Suppl. 18):27-32.
19. Grady TA, Piggot TA, L'Heureux F, Hill JL, Bernstein SE, Murphy DL. Double-blind study of adjuvant buspirone for fluoxetine-treated patiens with obsessive-compulsive disorder. Am J Psychiatry 1993;150:819-821.
20. Greist JH, Serlin RC, Katzelnick DJ, Kobak KA, Jefferson JW. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 1995;53:653-654.
21. Heykants J, Juany ML, Mannens G, Meulderans W, Snoeck E, Van Beijsterveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: A summary. J Clin Psychiatry 1994;55 (Suppl.5):13-17.
22. Hohangen F, Winkelmann G, Rasche-Räuchle H, Hand I, König A, Münchau N, Hiss H, Geiger-Kabisch C, Kappler C, Schramm P, Rey E, Aldenhoff J, Berger M. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Br J Psychiatry 1998;173(Suppl.35):71-78.
23. Jacobsen FM. Risperidone in the treatment of affective illness and obsessive-compulsive disorder. J Clin Psychiatry 1995;56:423-429.
24. Jenike M. Neurosurgical treatment of obsessive-compulsive disorder. Br J Psychiatry 1998;173(Suppl.35):79-90.
25. Kawahara T, Ueda Y, Mitsuyama Y. A case report of refraktory obsessive-compulsive disorder improved by risperidone augmentation of clomipramine treatment. Psychiatry and Clinical Neurosciences 2000; 54:599-601.
26. Khullar A, Chue P, Tibbo P. Quetiapine and obsessive-compulsive symptoms/OCS/: Case report and review of atypical antipsychotic-induced OCS. Journal of Psychiatry and Neuroscience 2001;26:55-59.
27. Koran M, Ringold AL, Elliot MA. Olanzapine augmentation for treatment-resistant obessive-compulsive disorder. J Clin Psychiatry 2000;61:514-517.
28. Krystal JH, Sibyl JP, Price LH, Woods SW, Heninger GR, Aghajanian GK, Charney DS. m-Chlorophenylpiperazine affects in neuroleptic-free schizophrenic patients: Evidence implicating serotoninergic systems in the positive symptoms of schizophrenia. Arch Gen Psychiatry 1993;50:624-635.
29. Levkovitch Y, Kronnenberg Y, Gaoni B. Can clozapine trigger OCD? J Am Acad Child Adolesc Psychiatry 1995;34:263.
30. Lykouras L, Zerva IM, Gournellis R, Malliori M, Rabavilas A. Olanzapine and obsessive-compulsive symptoms. European Neuropsycho-Pharmacology 2000;10:385-387.
31. Malison RT, McDougle CJ, Van Dyck CH, Scahill L, Baldwin RM, Seibyl JP, Price LH, Leckman JF, Innis RB. /123/I beta - CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-1361.
32. Marazziti D, Pallanti S. Effectiveness of olanzapine treatment for severe obsessive-compulsive disorder. Am J Psychiatry 1999;156:1834-1835.
33. McDougle CJ, Barr LC, Goodman WK, Pelton GH, Aronson SC, Anand A, Price LH. Lack of efficacy of clozapine monotherapy in refractory obsessive-compulsive disorder. Am J Psychiatry 1995;152:1812-1814.
34. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 2000;57:794-801.
35. McDougle CJ, Fleischmann RL, Eepperson CN, Wasylink S, Leckman JF, Price LH. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: Three cases. J Clin Psychiatry 1995;56:526-528.
36. McDougle CJ, Goodman WK, Leckman JF, Holzer JC, Barr LC, McCance-Katz EF, Heninger GR, Price LH. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive compulsive disorder. Am J Psychiatry 1993;150:647-649.
37. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patiens with and without tics. Arch Gen Psychiatry 1994;51:302-308.
38. McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. Am J Psychiatry 1990;147:652-654.
39. McDougle CJ, Price LH, Goodman WK, Charney DS, Heninger GR. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: A lack of efficacy. J Clin Psychopharmacol 1991;11:175-184.
40. Mezinárodni Klasifikace Nemocí. 10. Revize. Duševní Porucha a Poruchy Chování. Diagnostická Kritéria pro Výzkum. Praha: Psychiatrické centrum 1996;179.
41. Mohr N, Vythilingum B, Emsley RA, Stein DJ. Quetiapine augmentation of serotonin reuptake inhibitors in obsessive-compulsive disorder. Int Clin Psychopharmacol 2002;17:37-40.
42. Možný P, Prǎko J. Kognitivné-Behaviorálni Terapie. Úvod do Terapie a Praxe. Praha: Triton, 1999; 304.
43. Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry 1999;60: 256-259.
44. Pauls DL, Towbin KE, Leckamn JF, Zahner GE, Cohen DJ. Gilles de la Tourette's syndrome and obsessive-compulsive disorder. Evidence supporting a genetic relationship. Arch Gen Psychiatry 1986;43:1180-1182.
45. Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Mila-franchi A, Cassano GB. Risperidone augmentation in refractory obsessive-compulsive disorder: An open-label study. Int Cli Psychopharmacol 2000;15:297-301.
46. Piggot TA, Pato MT, L'Hereux F, Hill JL, Grover GN, Bernstein SE, Murphy DL. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991;11:242-248.
47. Piggot TA, Seay S. Biological treatments for obsessive-compulsive disorder. In: Swinson RP, Antony MM, Rachamn S, Richter MA, eds. Obsessive-Compulsive Disorder: Theory, Research and Treatment. New York: Guilford Press, 1998;298-326.
48. Potenza MN, Wasylink S, Loughurst JG, Epperson CN, McDougle CJ. Olanzapine augmentation of fluoxetine in the treatment of refractory obsessive-compulsive disorder. J Clin Psychopharmacol 1998; 18:423-424.
49. Ramasubbu R, Ravindran A, Lapierre Y. Serotonin and dopamine antagonism in obsessive-compulsive disorder: Effect of atypical antipsychotic drugs. Pharmacopsychiatry 2000;33:236-238.
50. Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder /OCD/. Psychopharmacology Bulletin 1996;32:677-682.
51. Rosenberg DR, Keshavan MS. Toward a neurodevelopmental model of obsessive-compulsive disorder. Biol Psychiatry 1998;43:623-640.
52. Salkovskis PM, Forrester E, Richards C. Cognitive-behavioural approach to understanding obsessional thinking. Br J Psychiatry 1998;173(Suppl.35):53-63.
53. Saxena S, Wang D, Bystritsky A, Baxter LR. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 1996;57:303-306.
54. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spenser KA, Feldman PD, Meltzer HY. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 2001;158:131-134.
55. Shapiro E, Shapiro AK, Fulop G, Hubbard M, Mandeli J, Nordlie J, Philips RA. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Touretteś syndrome. Arch Gen Psychiatry 1989;46:722-730.
56. Simpson HB, Gorfinkle KS, Liebowitz MR. Cognitive-behavioral therapy as adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder. An open trial. J Clin Psychiatry 1999;60:584-590.
57. Singer HS, Hahn IH, Moran TH. Abnormal dopamine uptake sites in postmortem striatum from patients with Tourette's syndrome. Annals of Neurology 1991;30:558-562.
58. Smolík P. Duševní a Behaviorální Poruchy. Průvodce Klasifikací, Nástin Nosologie, Diagnostika. Praha: Maxdorf s.r.o., 1996; 504.
59. Stein DJ, Houser C, Hawkridge S, Emsley RA. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders. J Clin Psychiatry 1997;58:119-122.
60. Stein DJ. Neurobiology of the obsessive-compulsive spectrum disorder. Review. Biol Psychiatry 2000;47:296-304.
61. Švestka J. Nová (atypická) antipsychotika 2. Generace. Remedia 1999; 9:366-385.
62. Weiss EL, Potenza MN, McDougle JC, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: An open-label case series. J Clin Psychiatry 1999;60:524-527.
63. Zohar J, Insel TR. Obsessive-compulsive disorder: Psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987;22:667-687.